Anne Rullier,Christophe Laurent
Anne Rullier
Guillaume Portier
Guillaume Portier
Hélène Fontaine,Karine Petitprez,Françoise Roudot-Thoraval et al.
Hélène Fontaine et al.
S Pol,P Sogni
S Pol
Second generation nucleos (t) idic analogues result in a complete viral suppression after 48 to 96 weeks of therapy in most patients, regardless of the virus (HBV genotype, wild type or pre-C mutant), the underlying liver disease (cirrhosis...
[Long-term therapy for chronic hepatitis B in HIV co-infected patients] [0.03%]
艾滋病合并慢性乙肝患者的长期抗病毒治疗策略
R Pais,Y Benhamou
R Pais
As human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are acquired through the same routes of contamination, the prevalence of HBV serological markers found in the HIV-infected population is approximately 7%. Liver-related morta...
A Kahloun,M Bourlière,F Zoulim
A Kahloun
Hepatitis B virus (HBV) genomic variability is responsible for the complexity of the viral quasi-species and its evolution during the course of infection. The persistence of infected cells promotes the selection of drug-resistant strains. T...
[HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome] [0.03%]
[乙肝表面抗原血清学清除的意义:治疗效果及长期预后的预测价值]
R Moucari,P Marcellin
R Moucari
Chronic hepatitis B is a major cause of liver disease worldwide, ranking as the first cause of cirrhosis and hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) is usually used as a qualitative marker for the diagnosis of hepatiti...